엔솔바이오사이언스 Stock: price and insider trades · South Korea
No insider purchase over the last 90 days. The latest, by 형인우, was filed 13 Jul 2026.
엔솔바이오사이언스: what insiders have been doing
엔솔바이오사이언스 is a Health Care company. Its directors and officers file their transactions with DART (FSS). In the past year (2 November 2025 to 2 November 2026), 4 filings came from 4 insiders.
No insider sold shares on the market over the period. Instead, the filings list 3 purchases totalling €13k, made by 3 insiders. The totals do not cover 2 filings with an undisclosed amount. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Among those who bought: 1 major shareholder and 1 senior executive. 문은정 filed the largest purchase, €13k, on 19 March 2026.
Compared with its exchange (2,655 companies, median 7 filings), a count of 4 filings is below the norm. Over the whole record (from 2021), the tally stands at 19 purchases and 2 sales.
The clock since the last published purchase (13 July 2026) now reads 120 days. Between a trade and the moment it shows up on DART (FSS), the median delay is 7 days. That lag is the time during which only the insider knows about the trade.
Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and UCB. This summary is built from DART (FSS) disclosures alone and does not predict where the share price will go.
Who traded when
BuySaleSince the insiders bought
- -15.9%Entry ₩12,700 · Close at T+30 ₩10,680
- -13.8%Entry ₩15,610 · Close at T+90 ₩13,448
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
· cache
- 621,829 sharesKRXDART:20260713000185Canonical exit: 11 Oct 2026 (T+90)
- 759,072 sharesKRXDART:20260527000359Canonical exit: 18 Aug 2026 (T+90)
- 1,396 shares@ ₩15,750.00100.0% of flowShareKRXDART:20260319000951Canonical exit: 17 Jun 2026 (T+90)
- 20,000 shares@ ₩9,441.3116100.0% of flowShareKRXDART:20260319000930
- 65,000 sharesShareKRXDART:20251002000426Canonical exit: 31 Dec 2025 (T+90)
- 4,319,000 sharesKRXDART:20250808000101Canonical exit: 4 Nov 2025 (T+90)
- 50,000 sharesShareKRXDART:20250808000115Canonical exit: 6 Nov 2025 (T+90)
- 400,000 sharesKRXDART:20250806000016Canonical exit: 4 Nov 2025 (T+90)
- 400,000 sharesShareKRXDART:20250806000025Canonical exit: 4 Nov 2025 (T+90)
- ●Executives0DART
- ●Executives0DART
- 1,730,692 sharesShareKRXDART:20250311000027Canonical exit: 9 Jun 2025 (T+90)
- ●Executives0DART
- Other0DART
- 550,055 sharesKRXDART:20250108000339
- 550,055 sharesKRXDART:20250106000392Canonical exit: 2 Apr 2025 (T+90)
- 241,438 sharesKRXDART:20240110000465
- 550,055 sharesKRXDART:20230710000133Canonical exit: 3 Sept 2023 (T+90)
- ●Executives0DART
- 550,055 sharesKRXDART:20230221000149Canonical exit: 22 May 2023 (T+90)
- 137,676 sharesKRXDART:20230210000851Canonical exit: 11 May 2023 (T+90)
- 550,055 sharesKRXDART:20221209000613Canonical exit: 9 Mar 2023 (T+90)
- ●Executives0DART
- 550,055 sharesKRXDART:20210810000213Canonical exit: 8 Nov 2021 (T+90)
- ShareKRXDART:20210614000277Canonical exit: 12 Sept 2021 (T+90)
25 of 28 declarations
About 엔솔바이오사이언스
Ensol Bioscience is a company operating in the healthcare and pharmaceutical sector, listed on the XKRX market. It focuses on developing innovative biopharmaceutical solutions.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
